Navigation Links
Drug in New Hepatitis C Clinical Trial
Date:8/24/2007

BRISBANE, Australia, Aug. 24 /PRNewswire/ -- Physicians at Southern Health have started a phase IIa clinical trial designed to test the efficacy of a new strategy for defeating hepatitis C viral infection, one of the toughest infectious diseases in the modern world.

Implicit Bioscience's drug, oglufanide disodium, which works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.

"The drugs currently in use fail to control this disease in about one half of all patients," said Dr Ian Frazer, Implicit's Chief Scientific Officer. "So there is a compelling need for new and better therapies, and we hope that oglufanide disodium may control or reverse the suppression of the immune system which the hepatitis virus uses to defeat our normally healthy defenses."

Dr Frazer is well known as the co-inventor of the recently approved vaccine for papillomavirus, which is designed to prevent cervical cancer.

Dr William Sievert, who is the Principal Investigator for the trial, welcomed the opportunity to study the action of oglufanide disodium in his busy liver diseases clinic at the Monash Medical Centre, which is part of the Southern Health network. "It is an important opportunity for patients to be involved in a new trial such as this, in which new treatment prospects are explored."

Oglufanide disodium was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by the privately-owned Brisbane biotech company Implicit Bioscience Pty Ltd in 2005.

The phase IIa trial of intranasal oglufanide disodium will complement the ongoing phase Ib study of subcutaneously administered drug at the Princess Alexandra Hospital in Brisbane.

Oglufanide disodium regulates the body's innate immune response to defeat in
'/>"/>

SOURCE Implicit Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
7. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
8. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
9. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
10. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
11. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... differs between the sexes, findings show, , TUESDAY, Feb. 2 ... boys, new research indicates. , ""Our study shows that the ... the same in boys as it is in girls," study ... University of Michigan, said in a university news release. "We ...
... , ... will reveal new statistics gathered by the Dark Report at The Executive War College on ... Miami, ... Adam Slone will present the Dark Report,s 2010 Executive Compensation and Benefits Survey at ...
... This release is available in French ... social difficulties simply because of the way they talk, ... McGill,s School of Communication Sciences and Disorders, has learned ... Parkinson,s disease, based solely on how they communicate. These ...
... , , MOUNT LAUREL, N.J. , Feb. 2 ... pleased to announce the opportunity for individuals interested in voluntary ... case manager certification program in the United States . ... CCM® credential, CCMC is dedicated to upholding rigorous standards for ...
... , LOS ANGELES , Feb. 2 LaVelle LaRue ... food! He did this without the help of Lap Band or any other ... a model/actor/comedian, LaVelle LaRue was fed up with eating the same ... did not have the time to cook himself tastier meal choices that were ...
... high risk of schizophrenia , TUESDAY, Feb. 2 (HealthDay ... schizophrenia and other psychotic disorders, fish oil may help ... study included 81 high-risk patients with either mild psychotic ... disorders, plus a decrease in daily functioning. These criteria ...
Cached Medicine News:Health News:Later Puberty Seen for Obese Boys 2Health News:Adam Slone to Present the 2010 Study on Executive Compensation Benefits for the Diagnostic Laboratory Industry 2Health News:Adam Slone to Present the 2010 Study on Executive Compensation Benefits for the Diagnostic Laboratory Industry 3Health News:Parkinson's disease research uncovers social barrier 2Health News:CCMC Accepting Applications for Voluntary Service on its Board of Commissioners 2Health News:CCMC Accepting Applications for Voluntary Service on its Board of Commissioners 3Health News:From 301 lbs Diabetic to Fast Food Six Pack Abs 2Health News:Fish Oil Helped Stave Off Psychosis in Study Patients 2
Inquire...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... ideal for PCR and other ... work where aerosol contamination might ... pipetting DNA/RNA solutions, infectious materials, ... applications requiring absolute sterility, they ...
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
Medicine Products: